A U.S. District Judge has granted class-action status to former Wyeth investors who accused the...


A U.S. District Judge has granted class-action status to former Wyeth investors who accused the Pfizer (PFE -0.1%) unit of misleading them about risks associated with its antidepressant drug Pristiq. The FDA rejected the drug in July, 2007 over potential serious heart and liver problems associated with its use. A Pfizer spokesperson says the company will continue to defend itself vigorously.

From other sites
Comments (3)
  • Goeleven
    , contributor
    Comments (617) | Send Message
     
    A new case before justice. Not Good for PFE
    18 Sep 2012, 11:02 AM Reply Like
  • spute
    , contributor
    Comments (71) | Send Message
     
    It's about TIME Pfizer fesses up!!! The public is OUTRAGED at all the lies being told them re: cherry picked data...downplayed side effects...MIS-filed adverse events w/Chantix!! I mean, REALLY? What an insult to our intelligence.

     

    Hopefully, former disgruntled Pfizer scientists will BLOW THE WHISTLE on what REALLY goes on behind big pharma closed doors!!!
    18 Sep 2012, 11:11 AM Reply Like
  • Goeleven
    , contributor
    Comments (617) | Send Message
     
    Really. That's new for me. spute Tks. for the info.
    18 Sep 2012, 11:48 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs